==> picture [157 x 72] intentionally omitted <==

Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au

Market Release

18 August 2021

Corum transformation continues

Corum Group Limited (ASX: COO) (Corum) is pleased to announce its full year results for FY21.

Group revenue $13.4m UP 26% on pcp
Underlying EBITDA $4.4m UP 237% on pcp
Underlying NPAT $2.2m UP 1,105% on pcp
Underlying EPS 0.41 cents per share, compared to 0.05 cents per share in pcp
Operating cashflow $3.2m UP 757% on pcp
Cash on hand $6.5m

Key operational highlights

Management and Board strengthened with Julian Sallabank appointed CEO and Jayne Shaw and Dennis Bastas appointed to the Board. Zoe Hiller appointed CFO and James Nevile appointed COO.
Completion of the PharmX acquisition. Corum acquired the remaining 57% of equity in PharmX for $7.9m
Successful capital raise. Corum undertook a 1 for 3 Non-renounceable Rights issue to raise $5.6m before costs at 4.2cps to part fund the PharmX acquisition
Strategic placement to Arrotex pharmaceuticals. Corum secured Arrotex pharmaceuticals, Australia’s largest generic and private label OTC company as a strategic shareholder. This placement raised a further $3.3m at 5.5cps.
Revenue of $13.4m was an increase of 26% on pcp aided by the PharmX acquisition. Expenses continue to be closely controlled
Underlying EBITDA of $4.4m was an increase of 237% on pcp.
Corum ended the year with a strong cash balance and is well positioned to take advantage of strategic opportunities as they occur
Cash from operating activities was $3.2m vs $0.4m in pcp

Commenting on the results, Corum Managing Director, Julian Sallabank said: “I am very pleased with the progress that we have achieved this year. We are strengthening our team which will enable us to execute on our strategy. We will continue to focus on profitable growth of our health business and are actively looking to augment that growth through acquisitions”.

==> picture [595 x 31] intentionally omitted <==

----- Start of picture text -----

Corum Group | Corum Health | Corum eCommerce | PharmX corumgroup.com.au
----- End of picture text -----

- ENDS -

==> picture [157 x 72] intentionally omitted <==

Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au

This announcement has been authorised for lodgment by Julian Sallabank, Managing Director

For further information contact:

Julian Sallabank, Managing Director

Investor email: [email protected]

About Corum Group

Corum Group Limited [ASX:COO] (Corum) is an Australian company limited by shares that owns businesses in technology and software development.

For more than 30 years Corum has been using its deep industry expertise and extensive relationships to develop Point-Of-Sale, Dispensing and Management software for pharmacy head offices and retail stores and a range of eCommerce and ordering solutions throughout Australia.

Corum is determined to offer the best solutions to its customers through the products, services and processes of each of its businesses.

==> picture [595 x 31] intentionally omitted <==

----- Start of picture text -----

Corum Group | Corum Health | Corum eCommerce | PharmX corumgroup.com.au
----- End of picture text -----

==> picture [244 x 451] intentionally omitted <==

Corum Group Limited

FY21 Results 18 August 2021

Important Notice & Disclaimer

This presentation has been prepared by Corum Group Limited (COO or the Company or Corum). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in COO, or as an inducement to purchase any shares in COO. No agreement to subscribe for securities in COO will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates an each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Although the Company believes that the expectations reflected in the forwardlooking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any

==> picture [58 x 25] intentionally omitted <==

FY21 Key Highlights

==> picture [624 x 52] intentionally omitted <==

----- Start of picture text -----

Financials
----- End of picture text -----

Revenue $13,382k , an increase of 26% on pcp
Heath Services $11,875k, up 35% on pcp
eCommerce $1,507k, down 17% on pcp
Underlying EBITDA $4.4m[(1)] compared to $1.3m[(2)] in pcp, up 237%
Underlying NPAT of $2.2m[(3)] compared to $0.2m[(4)] in pcp, up 1,105%
Underlying EPS of 0.41 cents per share[(3)] compared to 0.05 cents per share[(4)] in pcp
Operating cashflow was $3,162k in the year compared to $369k in pcp
Cash on hand at 30 June 2021 of $6.5m
- (1) Excluding PharmX + BAMM legal costs / restructuring / redundancy $(1.4)m (2) Excluding PharmX legal costs $(0.3)m
- (3) Excluding PharmX + BAMM legal costs / restructuring / redundancy $(1.4)m, BAMM Settlement $(1.5)m, fair value adjustments +$1.7m

==> picture [58 x 25] intentionally omitted <==

(4) Excluding PharmX legal costs $(0.3)m, impairment $(1.5)m, fair value adjustments +$1.8m

FY21 Ke Hi hli hts y g g

==> picture [624 x 25] intentionally omitted <==

----- Start of picture text -----

PharmX Acquisition
----- End of picture text -----

Acquisition of the 57% equity in PharmX that Corum did not already own
This acquisition was earnings per share accretive in the first year, as forecast

==> picture [624 x 25] intentionally omitted <==

----- Start of picture text -----

Capital Raising
----- End of picture text -----

Corum undertook a 1 for 3 Non-Renounceable Rights issue (“Offer”) to raise $5.6 million before costs at 4.2 cps as part funding for the acquisition
Strategic placement to Arrotex Pharmaceuticals raising a further $3.3m at 5.5 cps
The Corum Board and their related entities participated fully for their respective entitlements & collectively hold 28% of the listed equity

==> picture [624 x 25] intentionally omitted <==

----- Start of picture text -----

Corporate
----- End of picture text -----

Appointment of Julian Sallabank as CEO and Managing Director effective 1 September 2020. Completed a restructure to set the organisation up for future growth with additional skillsets and industry experience.
Board capabilities strengthened with the appointment of Jayne Shaw (Oct 20) and Dennis Bastas (Dec 20)
Secured Arrotex Pharmaceuticals as a strategic shareholder . Arrotex is Australia’s largest generic and private label OTC company servicing 3,400 pharmacies
Concluded BAMM agreement – Research & Development now in house providing greater control over product development

~~4~~

Our Pharmacy Software Solutions

Corum Health is a key enabler of Australian community pharmacy through it’s Dispense, Point of Sale and Head Office pharmacy digital infrastructure

Solutions

Medication dispense systems are highly regulated
ePrescribing ready in a post COVID environment
• Corum Clear Dispense ( CCD ) in market and expanding rapidly
Manage front of house cash collection
Also serve as stock ordering and control system Retail
• Corum Clear Retail ( CCR ) focused on enhancing existing functionality and performance
Pharmacy group management solutions
RPM is the market leading head office system
• Corum Clear Enterprise ( CCE ) currently in development

==> picture [58 x 25] intentionally omitted <==

Pharmacy Software Opportunities

Focus on regaining market share

90% of pharmacies are now affiliated with a group, banner, brand or buying group which supports this approach
Regaining market share by targeting these groups through our relationships and market leading Head Office product
Build on Dispense, Point of Sale and other product opportunities through these partnerships
We have identified some skill gaps and have invested appropriately into upskilling our workforce to take advantage of our growth opportunities
Streamlining product range combined with a disciplined approach to development spend will improve return on future investment

==> picture [58 x 25] intentionally omitted <==

PharmX Overview

PharmX is the pre-eminent electronic ordering gateway for Australian pharmacy with a long track record of delivering the stability and reliability required by the high order volumes of pharmacies

Key Pharmacy Benefits Key Supplier Benefits
• Access all wholesalers • Single access point to Australian pharmacy
• Broad range of POS systems •
supported including all major Facilitates electronic ordering vendors without customised interfaces
• Connecting 5,500+ • Increases ordering efficiency Increases pharmacy supply chain saving valuable staff time pharmacies to their efficiency suppliers
• Broad range of direct suppliers connected and accessible Connected Wholesalers Selected Connected Suppliers

==> picture [55 x 28] intentionally omitted <==

==> picture [54 x 28] intentionally omitted <==

==> picture [53 x 27] intentionally omitted <==

==> picture [52 x 27] intentionally omitted <==

==> picture [53 x 27] intentionally omitted <==

==> picture [58 x 25] intentionally omitted <==

PharmX Opportunities

Renewed strategic focus has delivered enhanced growth opportunities –the past 3 years of equity holder litigation that was a significant distraction to the strategic focus of PharmX, has been resolved through the acquisition

==> picture [32 x 307] intentionally omitted <==

==> picture [298 x 21] intentionally omitted <==

----- Start of picture text -----

Capital Investment
----- End of picture text -----

==> picture [297 x 21] intentionally omitted <==

----- Start of picture text -----

Additional Services
----- End of picture text -----

PharmX management have identified a range of potential additional services to further improve pharmacy supply chain efficiency

Corum will continue to provide PharmX with capital investment to achieve growth ambitions based on expected profitability and managed risk

We are further integrating between Corum software products and PharmX to provide a more complete offering, especially to groups

We have been working more collaboratively with vendors and wholesalers over the past 6 months on opportunities to enhance the platform

==> picture [298 x 21] intentionally omitted <==

----- Start of picture text -----

Extend Supplier Depth
----- End of picture text -----

==> picture [297 x 21] intentionally omitted <==

----- Start of picture text -----

Alternative Markets
----- End of picture text -----

Potential exists for the deployment of the PharmX technology platform across alternative market opportunities.

PharmX is focused on expanding the number of platform connected suppliers given the efficiency benefits for the pharmacy supply chain

PharmX has had some success in commencing the expansion into New Zealand and we are focused on escalating this growth. Revenue has almost doubled YoY and we expect this growth to continue.

A review of the pricing structure has made the platform a more appealing offering to smaller suppliers and we have seen an uplift in number of suppliers by 14% YoY. This growth has mainly occurred in the last 3-6 months and is just the beginning

We now also have a dedicated Sales Manager in PharmX to drive the revenue growth strategies 8

eCommerce

Corum eCommerce provides its clients a simple and efficient outsourced payment processing platform

==> picture [348 x 45] intentionally omitted <==

ReConnect oneCard

Secure payment solution primarily used by Real Estate agents without the need to maintain their own secure payment IT infrastructure

eCpay

Corporate grade payment solution offering customised features that is fast, reliable and secure and can be integrated to client requirements

Our eCommerce Solution

Secure PCI compliant payment gateway
Provides clients an efficient payment method for customers
Avoids the need for clients to maintain expensive payment systems
Full support desk service

Select Clients

==> picture [61 x 8] intentionally omitted <==

==> picture [57 x 26] intentionally omitted <==

==> picture [57 x 12] intentionally omitted <==

==> picture [57 x 18] intentionally omitted <==

==> picture [58 x 32] intentionally omitted <==

==> picture [50 x 21] intentionally omitted <==

==> picture [58 x 25] intentionally omitted <==

==> picture [262 x 454] intentionally omitted <==

Financials

FY21 Financial Snapshot

Results1 FY20 FY21 ∆ PCP Revenue $10,643 $13,382 26% Health Services2 $8,819 $11,875 35% eCommerce $1,824 $1,507 -17% Expenses ($9,648) ($10,320) 7% EBITDA (reported) $995 $3,062 208% EBITDA (underlying)3 $1,316 $4,435 237%	Results1 FY20 FY21 ∆ PCP Revenue $10,643 $13,382 26% Health Services2 $8,819 $11,875 35% eCommerce $1,824 $1,507 -17% Expenses ($9,648) ($10,320) 7% EBITDA (reported) $995 $3,062 208% EBITDA (underlying)3 $1,316 $4,435 237%	Results1 FY20 FY21 ∆ PCP Revenue $10,643 $13,382 26% Health Services2 $8,819 $11,875 35% eCommerce $1,824 $1,507 -17% Expenses ($9,648) ($10,320) 7% EBITDA (reported) $995 $3,062 208% EBITDA (underlying)3 $1,316 $4,435 237%	Results1 FY20 FY21 ∆ PCP Revenue $10,643 $13,382 26% Health Services2 $8,819 $11,875 35% eCommerce $1,824 $1,507 -17% Expenses ($9,648) ($10,320) 7% EBITDA (reported) $995 $3,062 208% EBITDA (underlying)3 $1,316 $4,435 237%
Revenue Health Services2 eCommerce Expenses EBITDA (reported) EBITDA (underlying)3	$10,643 $8,819 $1,824 ($9,648) $995 $1,316	$13,382 $11,875 $1,507 ($10,320) $3,062 $4,435	26% 35% -17% 7% 208% 237%

Sales Revenue ($000’s)

==> picture [301 x 97] intentionally omitted <==

----- Start of picture text -----

H2
$7,352 H2
$6,473 $5,348H2 $4,813H2 H2 $6,723H2
$4,605
H1
$8,201 $7,034H1 $5,828H1 $5,321H1 $4,511H1 $5,977H1
FY16 FY17 FY18 FY19 FY20 FY21
----- End of picture text -----

Underlying EBITDA ($000’s) & EBITDA Margin (%)[4]

Growth in Health revenue in line with expectations mainly due to PharmX contribution
Continued focus on organisational efficiencies and revenue generation delivered significant uplift in EBITDA
First revenue uplift since FY16 and EBITDA Margin of 35%

==> picture [309 x 152] intentionally omitted <==

----- Start of picture text -----

$5,000 40.0%
34.9%
$4,000
$4,435 30.0%
$3,000
20.0%
$2,000
10.0%
$1,000
- 0.0%
FY16 FY17 FY18 FY19 FY20 FY21
Underlying EBITDA EBITDA Margin
----- End of picture text -----

1Refer to Page 20 in the appendix for detailed financial statements
2 Includes unallocated segment revenue of $104k in FY21 and $90k in FY20

==> picture [58 x 25] intentionally omitted <==

3Adjusted to exclude one-off costs – see Page 12 Profit & Loss for detail on underlying calculations
4FY16 to FY19 is reported EBITDA, FY20 and FY21 are adjusted underlying EBITDA

Underlying Result Reconciliation

EBITDA	FY21	NPAT	FY21
		Underlying EBITDA	$4,435
Revenue	$13,382	Depreciation & Amortisation, interest and tax	($2,230)
Expenses	($10,320)	Underlying NPAT	$2,205
Reported EBITDA	$3,062	PharmX + BAMM legal costs / restructuring / redundancy	($1,373)
PharmX + BAMM legal costs / restructuring / redundancy	$1,373	BAMM settlement(1) FV adjustment on PharmX investment	($1,468) $1,727
Underlying EBITDA	$4,435	Reported NPAT	$1,091

Underlying Results Reconciliation

==> picture [559 x 117] intentionally omitted <==

----- Start of picture text -----

$2.2m
$4.4m
$1.4m
$m $1.5m $1.7m
$2.2m
$1.1m
Underlying EBITDA Depreciation & Underlying NPAT BAMM Settlement FV adjustment on PharmX + BAMM Reported NPAT
Amortisation, PharmX investment legals / restructuring
interest and tax / redundancy
----- End of picture text -----

==> picture [58 x 25] intentionally omitted <==

(1) This is the present value of the total consideration of $2m to be paid that has not met the asset recognition criteria to be capitalisedon the balance sheet as software product development. $800k paid in FY21 with $1.2m to be paid over the next 3 years.

Continued Positive Cashflow

Operating cashflow improvement has

Net cash from / (Used in) Operating Activities ($'000)[1]

==> picture [350 x 134] intentionally omitted <==

----- Start of picture text -----

$903
$559
$191
($1,315)
H1 FY20 H2 FY20 H1 FY21 H2 FY21
----- End of picture text -----

==> picture [155 x 10] intentionally omitted <==

----- Start of picture text -----

Receipts from Customers ($m)
----- End of picture text -----

==> picture [349 x 98] intentionally omitted <==

----- Start of picture text -----

$7.3
$6.6
$4.9 $4.8
H1 FY20 H2 FY20 H1 FY21 H2 FY21
----- End of picture text -----

been a key focus for new Board and has delivered positive results in FY21
FY21 operating cashflow of $1.5m vs prior year operating cashflow loss of $(1.1)m
Receipts from customers have

continued to grow and are up 10% HoH, and up 42% YoY driven by the contribution from PharmX

Disciplined cost control has reduced staff costs YoY. This has allowed room for investment into the right skill sets to grow revenues. Have invested progressively in new hires in Q4 and expect to see impact in next period.
Investment into our Clear Suite of
products and PharmX assets in the

current year has been a core focus to drive future revenue growth. We are continuing this investment to grow our customer base and increase the value of our product offering.

==> picture [58 x 25] intentionally omitted <==

1Adjusted to remove the impact of a net R&D tax incentive credit received

FY21 Summary

==> picture [59 x 59] intentionally omitted <==

Profitability restored & generating cash

First revenue uplift since FY16 and EBITDA Margin of 35% combined with positive run rate in FY21

==> picture [59 x 58] intentionally omitted <==

Platform For Growth

Healthtech Focus

Over the past 12 months Provides investors exposure Corum has put in place to a long established strengthened healthcare, pharmacy technology technology and commercial business with a strategy to capabilities to target growth augment growth through disciplined healthtech acquisitions

==> picture [59 x 59] intentionally omitted <==

Refreshed Board & management with significant equity

Corum has strengthened its pharmacy sector relationships and access through Board renewal[1] and the acquisition of PharmX

==> picture [58 x 25] intentionally omitted <==

1Refer to Page 18-19 in the appendix for director profiles

==> picture [262 x 453] intentionally omitted <==

Questions

==> picture [262 x 453] intentionally omitted <==

Appendix

Corporate Overview

==> picture [610 x 329] intentionally omitted <==

----- Start of picture text -----

Corum Group Limited (ASX:COO) Capital Structure
Share Price 8.0cps Shares on Issue (m) 596.8
Market Capitalisation $47.74m Options / Perf Rights (m) 4.0
Enterprise Value (Cash 30/06/21) $41.26m Diluted Issued Capital (m) 600.8
Share Price Performance [1]
12c 8
8c
4
4c
0c 0
Aug-20 Oct-20 Dec-20 Feb-21 Apr-21 Jun-21
Volume Share Price
Volume (m)
----- End of picture text -----

==> picture [58 x 25] intentionally omitted <==

1iress

Board & Management

==> picture [626 x 21] intentionally omitted <==

----- Start of picture text -----

Nick England - Chairman
----- End of picture text -----

==> picture [51 x 51] intentionally omitted <==

Nick has over 35 years of consulting and senior executive experience in Australia, the UK and Europe.

Nick held senior management roles with Alliance UniChem PLC (now AB Walgreens) which operates more than 18,000 pharmacies across multiple countries. As Group Director of Alliance UniChem, Nick was responsible for developing opportunities with key global network partners.

Nick’s experience includes roles with direct responsibility for managing strategy, sales and business performance.

==> picture [626 x 21] intentionally omitted <==

----- Start of picture text -----

Julian Sallabank - Managing Director
----- End of picture text -----

==> picture [44 x 44] intentionally omitted <==

Julian has vast experience in senior executive and board roles for both private and ASX listed companies operating in the medical technology and recruitment sectors.

Primary areas of expertise are strategic planning, commercialisation and organisational development of both domestic and international businesses.

Most recently Julian was Managing Director of an early stage medical innovation fund investing in and commercialising digital health, diagnostics, medtech and therapeutics; collaborating with the Murdoch Children’s Research Institute.

==> picture [626 x 23] intentionally omitted <==

----- Start of picture text -----

Jon Newbery - Non-Executive Director
----- End of picture text -----

==> picture [51 x 51] intentionally omitted <==

Jon brings to Corum over 30 years of senior executive and board roles for ASX listed companies in the technology, telecommunications, engineering and facilities management sectors.

Jon is currently Head of Corporate Finance and Projects for ASX listed Downer EDI with responsibility for strategic acquisitions and disposals for the group.

Previously Jon held roles as Chief Executive Officer of ASX listed Clarity OSS Limited and as Non-Executive Chairman of UK based platform developer IMX Software.

==> picture [58 x 25] intentionally omitted <==

Board & Management

==> picture [626 x 19] intentionally omitted <==

----- Start of picture text -----

Jayne Shaw - Non-Executive Director
----- End of picture text -----

==> picture [51 x 51] intentionally omitted <==

Ms Shaw has significant experience in healthcare management and an experienced clinical background in nursing. Ms Shaw has acted in senior management roles in two Australian private hospitals and established an Australian and international consulting business which was sold to Healthsouth, a large US Healthcare company.

After this, Jayne became the co-founder of Vision Group, a business that was successfully listed on the ASX.

Jayne has been a member of a number of private healthcare boards involved with specialist consolidation including cardiology, cancer care, orthopaedics, and women’s health and has continued to work with private equity firms on local and International Healthcare transactions.

Ms Shaw also holds positions on the boards of Mable Technologies, The Woolcock Research Institute, and The Citadel Group, and as Chairman of BCAL Diagnostics.

==> picture [626 x 20] intentionally omitted <==

----- Start of picture text -----

Dennis Bastas - Non-Executive Director
----- End of picture text -----

==> picture [51 x 51] intentionally omitted <==

Dennis has operated as an entrepreneur in Australia’s pharmaceutical sector since 2002 when he founded his first generic pharmaceutical company Genepharm. Over the past two decades he has gained extensive experience in the global pharmaceutical manufacturing industry and the Australian and Asian retail pharmacy market.

Dennis is currently the majority shareholder and Executive Chairman of two of Australia’s leading generic pharmaceutical companies, Arrotex Pharmaceuticals and Juno Pharmaceuticals.

Arrotex Pharmaceuticals is Australia’s largest generic pharmaceutical and private label OTC medicines company. Arrotex Pharmaceuticals was formed following the merger of Arrow Pharmaceuticals and Apotex Australia in July 2019 and is today Australia’s largest privately owned pharmaceutical company. Arrotex distributes medicines that account for over 30% of all PBS prescriptions dispensed in Australian pharmacies.

==> picture [58 x 25] intentionally omitted <==

Profit & Loss

H1'20	H2'20	FY'20	H1'21 H2'21 FY21 ∆ PCP $6,642 $6,740 $13,382 26% $5,862 $6,013 $11,875 34.7% $780 $727 $1,507 -17.4% ($1,040) ($895) ($1,935) 60.8% ($3,384) ($3,680) ($7,064) -1.6% ($53) ($53) ($106) -14.5% ($60) ($104) ($164) -65.4% ($385) ($533) ($918) 54.5% ($386) ($281) ($667) 35.8% ($92) $11 ($81) -48.1% - - - -100.0% $197 $418 $615 4.6%	H1'21 H2'21 FY21 ∆ PCP $6,642 $6,740 $13,382 26% $5,862 $6,013 $11,875 34.7% $780 $727 $1,507 -17.4% ($1,040) ($895) ($1,935) 60.8% ($3,384) ($3,680) ($7,064) -1.6% ($53) ($53) ($106) -14.5% ($60) ($104) ($164) -65.4% ($385) ($533) ($918) 54.5% ($386) ($281) ($667) 35.8% ($92) $11 ($81) -48.1% - - - -100.0% $197 $418 $615 4.6%	H1'21 H2'21 FY21 ∆ PCP $6,642 $6,740 $13,382 26% $5,862 $6,013 $11,875 34.7% $780 $727 $1,507 -17.4% ($1,040) ($895) ($1,935) 60.8% ($3,384) ($3,680) ($7,064) -1.6% ($53) ($53) ($106) -14.5% ($60) ($104) ($164) -65.4% ($385) ($533) ($918) 54.5% ($386) ($281) ($667) 35.8% ($92) $11 ($81) -48.1% - - - -100.0% $197 $418 $615 4.6%	H1'21 H2'21 FY21 ∆ PCP $6,642 $6,740 $13,382 26% $5,862 $6,013 $11,875 34.7% $780 $727 $1,507 -17.4% ($1,040) ($895) ($1,935) 60.8% ($3,384) ($3,680) ($7,064) -1.6% ($53) ($53) ($106) -14.5% ($60) ($104) ($164) -65.4% ($385) ($533) ($918) 54.5% ($386) ($281) ($667) 35.8% ($92) $11 ($81) -48.1% - - - -100.0% $197 $418 $615 4.6%	H1'21 H2'21 FY21 ∆ PCP $6,642 $6,740 $13,382 26% $5,862 $6,013 $11,875 34.7% $780 $727 $1,507 -17.4% ($1,040) ($895) ($1,935) 60.8% ($3,384) ($3,680) ($7,064) -1.6% ($53) ($53) ($106) -14.5% ($60) ($104) ($164) -65.4% ($385) ($533) ($918) 54.5% ($386) ($281) ($667) 35.8% ($92) $11 ($81) -48.1% - - - -100.0% $197 $418 $615 4.6%

$5,011	$5,632	$10,643	$6,642	$6,740 $13,382			26%
$4,056 $955 ($574) ($3,849) ($85) ($239) ($288) ($95) ($21) - $225	$4,763 $869 ($629) ($3,327) ($39) ($235) ($306) ($396) ($135) ($18) $363	$8,819 $1,824 ($1,203) ($7,176) ($124) ($474) ($594) ($491) ($156) ($18) $588	$5,862 $780 ($1,040) ($3,384) ($53) ($60) ($385) ($386) ($92) - $197	$6,013 $11,875 $727 $1,507 ($895) ($1,935) ($3,680) ($7,064) ($53) ($106) ($104) ($164) ($533) ($918) ($281) ($667) $11 ($81) - - $418 $615			34.7% -17.4% 60.8% -1.6% -14.5% -65.4% 54.5% 35.8% -48.1% -100.0% 4.6%
($4,926)	($4,722)	($9,648)	($5,203)	($5,117)	($10,320)		7.0%

$85	$910	$995	$1,439	$1,623	$3,062		207.7%

$139	$1,177	$1,316	$2,211	$2,224	$4,435		237.0%
($383)	($418)	($801)	($781)	($1,045) ($1,826)			128.0%
($244)	$759	$515	$1,430	$1,179	$2,609		406.6%
($24) $18	($26) ($300)	($50) ($282)	($20) $91	($116) ($136) ($359) ($268)			172.0% -5.0%
($250)	$433	$183	$1,501	$704	$2,205		1104.9%
($54) - -	($267) $314 -	($321) $314 -	($772) $1,727 ($1,468)	($601) ($1,373) - $1,727 - ($1,468)		519.9%
($304)	$480	$176	$988	$103	$1,091		519.9%

==> picture [58 x 25] intentionally omitted <==

Balance Sheet

==> picture [58 x 25] intentionally omitted <==

Balance Sheet (A$000's) Current assets Cash and cash equivalents Trade and other receivables Inventories Income tax receivable Other assets Total Non-current assets Investments Property, plant and equipment Right of use assets Intangibles Deferred tax assets Security deposits Total Total assets Current Liabilities Trade and other payables Provisions Lease Liability Deferred revenue Total Non-current liabilities Other payables Provisions Lease Liability Deferred Tax liability Total Total Liabilities Net assets Equity	FY'20	FY'21
	$2,323 $6,478 $3,826 $864 $64 $34 $1,700 $1,548 $1,928 $1,492 $9,841 $10,416 $2,686 - $525 $495 $702 $296 $4,674 $19,285 $551 $804 $199 $51 $9,337 $20,931 $19,178 $31,347 $3,628 $4,953 $1,202 $1,054 $422 $280 $226 $100 $5,478 $6,387 - $726 $192 $120 $311 $41 - $1,143 $503 $2,030 $5,981 $8,417 $13,197 $22,930
	$9,841	$10,416
	$2,686 $525 $702 $4,674 $551 $199	- $495 $296 $19,285 $804 $51
	$9,337	$20,931

	$19,178	$31,347
	$3,628 $1,202 $422 $226	$4,953 $1,054 $280 $100
	$5,478	$6,387
	- $192 $311 -	$726 $120 $41 $1,143
	$503	$2,030

	$5,981	$8,417

	$13,197	$22,930

Issued capital	$89,724	$98,366
Reserves	$18	$18
Accumulated losses	($76,545)	($75,454)
Total equity	$13,197	$22,930

Cashflow

Cash flow (A$000's) FY’20 FY’21	Cash flow (A$000's) FY’20 FY’21	Cash flow (A$000's) FY’20 FY’21

Cash flows from operating activities
Receipts from customers	$9,773	$13,887
Payments to suppliers and employees	($11,238)	($12,534)
Interest and other revenue received	$341	$108
Income tax paid	($281)	($272)
Research and development incentive	$1,774	$1,973
Net cash from operating activities	$369	$3,162

Cash flows from investing activities
Payments for property, plant and equipment	($156)	($300)
Payments for intangible assets	($3,128)	($3,789)
Acquisition of subsidiary	-	($2,097)
Proceeds from security deposits	$874	-
Payment for security deposits	($51)	-
Investment in unlisted entity	($875)	-
Net cash used in investing activities	($3,336)	($6,186)

Cash flows from financing activities
Proceeds from issue of ordinary shares	$3,660	$8,936
Share issue transaction costs	($302)	($392)
Principal paid on lease liabilities	($351)	($434)
Distributions paid	-	($896)
Interest paid on lease liabilities	($50)	($35)
Net cash from financing activities	$2,957	$7,179


Net increase/ (decrease) in cash and cash equivalents	($10)	$4,155
Cash and cash equivalents at beginning of the financial year	$2,333	$2,323

Cash and cash equivalents at the end of the financial year	$2,323	$6,478

==> picture [58 x 25] intentionally omitted <==

Share Registry

Top holders as of 12 August 2021

Rank	Name	Units	% Units
1	LUJETA PTY LTD	95,746,043	16.04%
2	ARROTEX INVESTMENTS HOLDING 1 PTY LTD	60,000,000	10.05%
3	NATIONAL NOMINEES LIMITED	38,033,657	6.37%
4	MERSAULT PTY LTD	26,766,667	4.49%
5	BENKI PTY LTD	19,655,748	3.29%
6	MR DAVID GERALD MANUEL & MS ANNE ELIZABETH LEARY	18,666,667	3.13%
7	LYELL PTY LTD	17,388,974	2.91%
8	MILBURN PTY LTD	16,088,895	2.70%
9	MR JOHN LAGANA	15,621,734	2.62%
10	GINGA PTY LTD	14,414,488	2.42%
11	MRS PENELOPE KING	13,333,334	2.23%
12	SANDHURST TRUSTEES LTD	13,283,372	2.23%
12	LINK ENTERPRISES (INTERNATIONAL) PTY LTD	13,090,345	2.19%
14	MR GRANT POVEY	12,000,000	2.01%
15	SEVENIRON PTY LTD	12,000,000	2.01%
16	LYELL PTY LTD	10,666,666	1.79%
17	CANCELER PTY LTD	9,150,000	1.53%
17	MR DAVID GERALD MANUEL & MS ANNE ELIZABETH LEARY	8,000,000	1.34%
19	MR TYSON WELLMAN	8,000,000	1.34%
20	GABODI PTY LIMITED	7,197,334	1.21%
Total Top 20	holders of FULLY PAID ORDINARY	429,103,924	71.91%
Total issued capital of FULLY PAID ORDINARY		596,756,789	100.00%

==> picture [58 x 25] intentionally omitted <==

==> picture [255 x 454] intentionally omitted <==

Corum Group Limited

Contact: [email protected]

AI assistant

PHARMX TECHNOLOGIES LIMITED — Annual Report 2021

65560_rns_2021-08-17_b1264eb5-ebb1-4bff-a350-b03943ea3138.pdf

Market Release

18 August 2021

Corum transformation continues

Key operational highlights

For further information contact:

About Corum Group

Corum Group Limited

Important Notice & Disclaimer

FY21 Key Highlights

FY21 Ke Hi hli hts y g g

Our Pharmacy Software Solutions

Solutions

Pharmacy Software Opportunities

PharmX Overview

PharmX Opportunities

eCommerce

ReConnect oneCard

eCpay

Our eCommerce Solution

Select Clients

Financials

FY21 Financial Snapshot

Sales Revenue ($000’s)

Underlying EBITDA ($000’s) & EBITDA Margin (%)[4]

Underlying Result Reconciliation

Continued Positive Cashflow

Net cash from / (Used in) Operating Activities ($'000)[1]

FY21 Summary

Questions

Appendix

Corporate Overview

Board & Management

Board & Management

Profit & Loss

Balance Sheet

Cashflow

Share Registry

Top holders as of 12 August 2021

Corum Group Limited

More from PHARMX TECHNOLOGIES LIMITED

PHARMX TECHNOLOGIES LIMITED Annual Report 2021